<DOC>
	<DOCNO>NCT03079921</DOCNO>
	<brief_summary>To determine effect sympathetic neural hormonal ( epinephrine ) input islet cell hormonal response insulin-induced hypoglycemia type 1 diabetic recipient intrahepatic islet transplantation . We hypothesize α-adrenergic ( neural ) blockage abolish insulin-mediated suppression C-peptide , attenuate α-cell glucagon secretion hypoglycemia , β-adrenergic ( hormonal ) blockage effect . Glucose counterregulatory response measure hyperinsulinemic euglycemic-hypoglycemic clamp three occasion randomize , double-blind administration α-adrenergic blocker phentolamine , β-adrenergic blocker propranolol , placebo . The demonstration neural rather hormonal regulation transplant islet cell response hypoglycemia critical understanding mechanism protection hypoglycemia afford intrahepatically transplant .</brief_summary>
	<brief_title>Adrenergic System Islet Transplantation</brief_title>
	<detailed_description>This study design test hypothesis α-adrenergic ( neural ) blockade abolish insulin-mediated suppression C-peptide , attenuate α-cell glucagon secretion hypoglycemia , β-adrenergic ( hormonal ) blockade effect . Glucose counterregulatory response measure hyperinsulinemic euglycemic-hypoglycemic clamp three occasion randomize , double-blind administration α-adrenergic blocker phentolamine , β-adrenergic blocker propranolol , placebo . The demonstration neural rather hormonal regulation transplant islet cell response hypoglycemia critical understanding mechanism protection hypoglycemia afford intrahepatically transplant islet . Glucose counterregulation study type 1 diabetic recipient extrahepatic islet transplantation . Comparison glucose counterregulatory response measure hyperinsulinemic euglycemic-hypoglycemic clamp compare obtain type 1 diabetic recipient intrahepatic islet transplantation study placebo condition . Glucose counterregulation directly compare recipient intrahepatic auto- allo-islet transplantation . Direct comparison glucose counterregulatory response experimental condition require understand whether mechanism glucagon response may important report hypoglycemia affect pancreatectomized recipient islet auto-transplantation .</detailed_description>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Phentolamine</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<mesh_term>Adrenergic Agents</mesh_term>
	<criteria>GROUP 1 1 . Male female subject age 21 65 year age . 2 . Subjects able provide write informed consent comply procedure study protocol . 3 . Clinical history compatible type 1 diabetes onset disease &lt; 40 year age insulindependent &gt; 10 year time islet transplantation &gt; 6 month study . 4 . Stable islet graft function define Cpeptide &gt; 0.5 ng/ml insulinindependent insulindependent daily insulin requirement &lt; 0.2 units/kg•d maintain HbA1c &lt; 7.0 % . 5 . Use standard immunosuppression consist tacrolimus without sirolimus mycophenolic acid . Substitutions tacrolimus cyclosporine , sirolimus mycophenolic acid azathioprine permissible stable 3 month . Prednisone allowable 5 mg daily . GROUP 1 1 . BMI ≥ 30 kg/m2 . 2 . Insulin requirement ≥ 0.2 units/kg•day . 3 . HbA1c ≥ 7.0 % . 4 . Uncontrolled hypertension : systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 100 mmHg . 5 . History cardiovascular disease , include coronary artery , cerebrovascular peripheral vascular disease , current use βblocker therapy . 6 . Bronchial asthma . 7 . Abnormal kidney function : Estimated glomerular filtration rate ( eGFR ) &lt; 60 ml/min/1.73 m2 . 8 . Abnormal liver function : persistent elevation liver function test &gt; 1.5 time upper limit normal . 9 . Untreated hypothyroidism , Addison 's disease , Celiac disease . 10 . Anemia : baseline hemoglobin concentration &lt; 11 g/dl woman &lt; 12 g/dl men . 11 . Presence seizure disorder relate prior severe hypoglycemia . 12 . Use glucocorticoid great 5 mg prednisone daily , equivalent physiologic dose hydrocortisone . 13 . For female participant childbearing potential : Positive pregnancy test , presently breastfeed , unwillingness use effective contraceptive measure duration study participation . Oral contraceptive , intrauterine device , Norplant® , DepoProvera® , barrier device spermicide acceptable contraceptive method ; condom use alone acceptable . 14 . Treatment antidiabetic medication insulin within 4 week enrollment . 15 . Use investigational agent within 4 week enrollment . 16 . Any medical condition , opinion PI , interfere safe completion study Inclusion Criteria GROUP 2 1 . Male female subject age 21 65 year age . 2 . Subjects able provide write informed consent comply procedure study protocol . 3 . Clinical history compatible type 1 diabetes onset disease &lt; 40 year age insulindependent &gt; 10 year time islet transplantation &gt; 6 month study . 4 . Stable islet graft function define Cpeptide &gt; 0.5 ng/ml insulinindependent insulindependent daily insulin requirement &lt; 0.2 units/kg•d maintain HbA1c &lt; 7.0 % . 5 . Use standard immunosuppression consist tacrolimus without sirolimus mycophenolic acid . Substitutions tacrolimus cyclosporine , sirolimus mycophenolic acid azathioprine permissible stable 3 month . Prednisone allowable 5 mg daily . GROUP 2 1 . BMI ≥ 30 kg/m2 . 2 . Insulin requirement ≥ 0.2 units/kg•day . 3 . HbA1c ≥ 7.0 % . 4 . Uncontrolled hypertension : systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 100 mmHg . 5 . Active cardiovascular disease , include coronary artery , cerebrovascular peripheral vascular disease . 6 . Abnormal kidney function : eGFR &lt; 60 ml/min/1.73 m2 . 7 . Abnormal liver function : persistent elevation liver function test &gt; 1.5 time upper limit normal . 8 . Untreated hypothyroidism , Addison 's disease , Celiac disease . 9 . Anemia : baseline hemoglobin concentration &lt; 11 g/dl woman &lt; 12 g/dl men . 10 . Presence seizure disorder relate prior severe hypoglycemia . 11 . Use glucocorticoid great 5 mg prednisone daily , equivalent physiologic dose hydrocortisone . 12 . For female participant childbearing potential : Positive pregnancy test , presently breastfeed , unwillingness use effective contraceptive measure duration study participation . Oral contraceptive , intrauterine device , Norplant® , DepoProvera® , barrier device spermicide acceptable contraceptive method ; condom use alone acceptable . 13 . Treatment antidiabetic medication insulin within 4 week enrollment . 14 . Use investigational agent within 4 week enrollment . 15 . Any medical condition , opinion PI , interfere safe completion study Inclusion Criteria GROUP 3 Patients meet follow criterion eligible participation Group 3 study : 1 . Male female subject age 21 65 year age . 2 . Subjects able provide write informed consent comply procedure study protocol . 3 . Clinical history compatible total pancreatectomy autologous islet transplantation &gt; 6 month study . 4 . Stable islet graft function define Cpeptide &gt; 0.5 ng/ml insulinindependent insulindependent daily insulin requirement &lt; 0.2 units/kg•d maintain HbA1c &lt; 7.0 % . GROUP 3 1 . BMI ≥ 30 kg/m2 . 2 . Insulin requirement ≥ 0.2 units/kg•day . 3 . HbA1c ≥ 7.0 % . 4 . Uncontrolled hypertension : systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 100 mmHg . 5 . Active cardiovascular disease , include coronary artery , cerebrovascular peripheral vascular disease . 6 . Abnormal kidney function : eGFR &lt; 60 ml/min/1.73 m2 . 7 . Abnormal liver function : persistent elevation liver function test &gt; 1.5 time upper limit normal . 8 . Anemia : baseline hemoglobin concentration &lt; 11 g/dl woman &lt; 12 g/dl men . 9 . Presence seizure disorder relate prior severe hypoglycemia . 10 . Use glucocorticoid great 5 mg prednisone daily , equivalent physiologic dose hydrocortisone . 11 . For female participant childbearing potential : Positive pregnancy test , presently breastfeed , unwillingness use effective contraceptive measure duration study participation . Oral contraceptive , intrauterine device , Norplant® , DepoProvera® , barrier device spermicide acceptable contraceptive method ; condom use alone acceptable . 12 . Treatment antidiabetic medication insulin within 4 week enrollment . 13 . Use investigational agent within 4 week enrollment . 14 . Any medical condition , opinion PI , interfere safe completion study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Islet Graft Function</keyword>
	<keyword>Islet Cell transplantation</keyword>
	<keyword>Auto-islet transplantation</keyword>
	<keyword>Intra-hepatic islet</keyword>
	<keyword>Extra-hepatic islet</keyword>
</DOC>